PharmAust has confirmed that its flagship anti-cancer drug, Monepantel, produced using the recently determined “GMP” process, continues to demonstrate the drug’s expected ability to kill cancer cells while having little or no impact on non-cancerous cells. Further pre-clinical molecular pathway targeting studies will now be carried out to improve the company’s understanding of how the drug kills cancer cells.